Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Ulrich Duehrsen"'
Autor:
Christof Scheid, Pieter Sonneveld, Ingo G.H. Schmidt-Wolf, Bronno van der Holt, Laila el Jarari, Uta Bertsch, Hans Salwender, Sonja Zweegman, Igor Wolfgang Blau, Edo Vellenga, Katja Weisel, Michael Pfreundschuh, Kon-Siong Jie, Kai Neben, Helgi van de Velde, Ulrich Duehrsen, M. Ron Schaafsma, Walter Lindemann, Marie José Kersten, Norma Peter, Mathias Hänel, Sandra Croockewit, Hans Martin, Shulamiet Wittebol, Gerard MJ Bos, Marinus van Marwijk-Kooy, Pierre Wijermans, Hartmut Goldschmidt, Henk M. Lokhorst
Publikováno v:
Haematologica, Vol 99, Iss 1 (2014)
Renal impairment is frequent in patients with multiple myeloma and is correlated with an inferior prognosis. This analysis evaluates the prognostic role of renal impairment in patients with myeloma treated with bortezomib before and after autologous
Externí odkaz:
https://doaj.org/article/f8e3a1869ee04ce7b7ebbc39988ad088
Autor:
Jan Boegeholz, Stefan K. Alig, Brian Sworder, Joseph Schroers-Martin, Charles Macaulay, Alexander F.M. Craig, Ulrich Duehrsen, Andreas Hüttmann, Jason Westin, Hua-Jay J. Cherng, David B. Miklos, Matthew J Frank, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh
Publikováno v:
Blood. 140:8609-8610
Autor:
Maximilian Diehn, David M. Kurtz, Alexander F.M. Craig, Lyron Co Ting Keh, Michael C. Jin, Mark Roschewski, Gianluca Gaidano, Andre Schultz, Chih Long Liu, Andreas Huettmann, Davide Rossi, Florian Scherer, Wyndham H. Wilson, Joanne Soo, Jacob J. Chabon, Stefan Alig, Rene-Olivier Casasnovas, Jason R. Westin, Ash A. Alizadeh, Ulrich Duehrsen
7565 Background: Detection of circulating tumor DNA (ctDNA) has prognostic value in diverse tumors, including DLBCL. Despite uses for assessing molecular response to therapy, current methods using immunoglobulin or hybrid-capture sequencing have subo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd2cba39b5dcdfbd665162ed91a55542
Autor:
Ioannis Anagnostopoulos, Norbert Meidenbauer, Michael Heuser, Dptldsg, Christiane Pott, Ilske Oschlies, Christian Schmidt, Heiner Zimmermann, Matthias Ritgen, Ulrich Duehrsen, Christian Koenecke, D Hahn, Reiner Siebert, Martin Dreyling, Ralf Ulrich Trappe
8045 Background: The PTLD-1 trials have established risk-stratified sequential treatment of B-cell PTLD. After rituximab induction, patients (pts) in complete remission (25 %) received rituximab consolidation, while all others received R-CHOP. The PT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b65ae62e1d72a10a0bdef5015e702276
Autor:
Marian Stevens-Kroef, M. van Marwijk Kooy, Henk M. Lokhorst, Hans-Walter Lindemann, Anna Potamianou, Gerard M. J. Bos, B. van der Holt, Igor Wolfgang Blau, Annemiek Broijl, Christoph Scheid, Peter Brossart, Pieter Sonneveld, Sonja Zweegman, R. Schaafsma, Sandra Croockewit, Reinier Raymakers, Le Jarari, Ulrich Duehrsen, H Salwender, Jens Hillengass, Dirk Hose, Elias K. Mai, Anna Jauch, Marc-Steffen Raab, Michael Pfreundschuh, Thomas Hielscher, Paula F. Ypma, Marie-Jose Kersten, Katja Weisel, Edo Vellenga, H. Goldschmidt, Uta Bertsch
Publikováno v:
Leukemia, 32(2), 383-390. Nature Publishing Group
Leukemia, 32, 2, pp. 383-390
Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, L, Salwender, H J & Sonneveld, P 2018, ' Bortezomib before and after high-dose therapy in myeloma : long-term results from the phase III HOVON-65/GMMG-HD4 trial ', Leukemia, vol. 32, no. 2, pp. 383-390 . https://doi.org/10.1038/leu.2017.211
Leukemia, 32(2), 383. Nature Publishing Group
Leukemia, 32, 383-390
Leukemia, 32, 2, pp. 383-390
Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, L, Salwender, H J & Sonneveld, P 2018, ' Bortezomib before and after high-dose therapy in myeloma : long-term results from the phase III HOVON-65/GMMG-HD4 trial ', Leukemia, vol. 32, no. 2, pp. 383-390 . https://doi.org/10.1038/leu.2017.211
Leukemia, 32(2), 383. Nature Publishing Group
Leukemia, 32, 383-390
The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell trans
Autor:
Marika Mende, Malte von Bonin, Antje Schubert, Anne Kubasch, Richard Noppeney, Marion Subklewe, Sabine Kayser, Friedrich Stoelzel, Michael Kramer, Gesine Bug, Johannes Schetelig, Gerhard Ehninger, Sebastian Stasik, Schumacher Martin, Christian Thiede, Jan-Henrik Mikesch, Juergen Novotny, Katharina Götze, Mathias Haenel, Anke Mütherig, Alwin Krämer, Dominik Wolf, Regina Herbst, Karsten Spiekermann, Lars Fransecky, Tilmann Bochtler, Uwe Platzbecker, Christoph Röllig, Carsten Müller-Tidow, Jan Moritz Middeke, Katja Sockel, Matthias Stelljes, Hubert Serve, Claudia D. Baldus, Ulrich Duehrsen, Martin Bornhäuser
Publikováno v:
Blood. 136:10-11
Background: Monitoring of measurable residual disease (MRD) in patients (pts) with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who achieve complete remission (CR) can predict hematological relapse. Recently published data
Autor:
Ulrich Duehrsen, Daniel R Engel, Pradeep Kumar Patnana, Aniththa Thivakaran, Judith Schuette, Daria Frank, Yahya Saleh Al-Matary, Cyrus Khandanpour
Gfi1 (Growth factor independence 1) is a transcription factor that influences the stem cell capacity of hematopoietic stem cells (HSCs) as well as their differentiation into the myeloid and lymphoid lineage. Loss of Gfi1 impedes the repopulation capa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae638fa3b661c469e55f84eea600b7eb
https://doi.org/10.1101/625715
https://doi.org/10.1101/625715
Autor:
Kai Neben, Anja Seckinger, Stephan Fuhrmann, Elias K. Mai, Henk M. Lokhorst, Uta Bertsch, Jana Schlenzka, Pieter Sonneveld, Hartmut Goldschmidt, Ulrich Duehrsen, Hans Salwender, Hans-Walter Lindemann, Markus Munder, Igor Wolfgang Blau, Marc S. Raab, Marc-A. Baertsch, Jan Duerig, Thomas Hielscher, Christof Scheid, Katja Weisel, Steffen Luntz, Mathias Haenel, Dirk Hose, Peter Brossart, Anna Jauch, Hans Martin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab310bd6fe6e2d55afb497a2a9ca8ce2
Autor:
Karin Menhart, Jirka Grosse, Viola Poeschel, Marita Ziepert, Dirk Hellwig, Stephanie Angel, Michael Pfreundschuh, Dominic Kaddu-Mulindwa, F. Barbato, Ken Herrmann, Andreas Hüttmann, Ulrich Duehrsen, Gerhard Held, Bettina Altmann, Stephan Stilgenbauer
BACKGROUND: According to the Lugano classification (Cheson et al., JCO 2014, 32: 3059-3067) fludeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) is the standard for evaluation and staging of aggressive non-Hodgk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59aa188507b13a6dde99d5f17e9711d2
Autor:
Katja Weisel, Marian Stevens-Kroef, Thomas Hielscher, Marc S. Raab, Annemiek Broyl, Stephan Stilgenbauer, Christof Scheid, Dirk Hose, Peter Brossart, Anna Jauch, Marie José Kersten, Hartmut Goldschmidt, Paula F. Ypma, Uta Bertsch, Elias K. Mai, Pieter Sonneveld, Igor Wolfgang Blau, Marinus van Marwijk Kooij, Gerard M. J. Bos, Ulrich Duehrsen, Edo Vellenga, Kai Neben, Hans Salwender, Sandra Croockewit, Henk M. Lokhorst, Bronno van der Holt, R. Schaafsma, Reinier Raymakers, Jens Hillengass, Sonja Zweegman, Hans-Walter Lindemann
Publikováno v:
Blood, 134. AMER SOC HEMATOLOGY
Background: Novel agents such as IMIDs and proteasome inhibitors have substantially changed the therapeutic landscape in the first line treatment of multiple myeloma (MM). Better response rates and prolonged progression-free survival have lead to an